The PREVAIL Trial Shows That Enzalutamide Not Only Increases Overall Survival Over Placebo, It Also Delays the Onset Of The First Skeletal Event

Analysis of the PREVAIL Trial showed that Enzalutamide (Xtandi) significantly increased overall survival and radiographic progression-free survival compared with placebo in men with prostate cancer who were asymptomatic and minimally symptomatic, chemotherapy-naive and who had metastatic castration-resistant prostate cancer (mCRPC).

Now, an additional analysis of the data has shown the effect enzalutamide also has on health-related quality of life (HRQoL). These criteria include pain and skeletal-related events experienced during the trial.

The researchers utilized the Functional Assessment of Cancer Th